NCT03583164: A trial that was reported late by F2G Biotech GmbH
This trial has reported, although it was 124 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT03583164 |
|---|---|
| Title | Phase IIb Study of F901318 as Treatment of Invasive Fungal Infections Due to Lomentospora Prolificans, Scedosporium Spp., Aspergillus Spp., and Other Resistant Fungi in Patients Lacking Suitable Alternative Treatment Options |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 6, 2018 |
| Completion date | Feb. 10, 2023 |
| Required reporting date | Feb. 10, 2024, midnight |
| Actual reporting date | June 13, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | 124 |